Pharmacokinetics and Pharmacodynamics Practice Questions

Q: The action of intravenous thiopentone is terminated by which mechanism?

Redistribution. ### Explanation **Correct Option: C. Redistribution** Thiopentone is a highly lipid-soluble ultra-short-acting barbiturate [1]. When administered intravenously, it rapidly crosses the blood-brain barrier and reaches peak concentrations in the brain (a highly perfused organ) within seconds, leading to immediate induction of anesthesia [5]. However, its action is terminated not by metabolism, but by **redistribution** [1], [3]. As the plasma concentration falls, the drug diffuses out of the brain and moves into less perfused but larger volume tissues, such as skeletal muscles and eventually adipose tissue [1]. This shift lowers the concentration in the brain below the threshold for anesthesia, causing the patient to wake up within 5–10 minutes [2]. **Why other options are incorrect:** * **A. Rapid renal excretion:** Thiopentone is highly lipophilic and undergoes extensive tubular reabsorption; therefore, renal excretion of the unchanged drug is negligible. * **B & D. Oxidation and Conjugation:** While thiopentone is eventually metabolized in the liver (primarily via oxidation), the rate of metabolism is slow (~10–15% per hour) [3]. Metabolism is responsible for the ultimate elimination of the drug from the body, but it is too slow to account for the rapid recovery from a single induction dose [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Context-Sensitive Half-time:** Thiopentone has a long elimination half-life. If given as a repeated infusion, the "storage" sites (fat) become saturated, and recovery then depends on metabolism rather than redistribution, leading to prolonged recovery times [3], [4]. * **Hanging-over effect:** Due to its slow metabolism and gradual release from fat stores, patients often experience post-operative drowsiness [2]. * **Contraindication:** It is strictly contraindicated in **Acute Intermittent Porphyria** as it induces ALA synthase.

Q: A dose-response curve of diazepam was produced alone and in the presence of flumazenil. Which of the following is true regarding the effect of flumazenil on the graph?

Decrease in potency and no effect on efficacy. ### Explanation **Concept: Competitive Antagonism** The interaction between **Diazepam** (a benzodiazepine agonist) and **Flumazenil** (a benzodiazepine antagonist) is the classic example of **competitive (reversible) antagonism**. 1. **Why Option A is Correct:** In competitive antagonism, both the agonist and the antagonist compete for the same binding site on the receptor (GABA-A receptor). * **Potency:** Because the antagonist occupies some receptors, a higher concentration of the agonist (Diazepam) is required to achieve the same effect. This shifts the Dose-Response Curve (DRC) to the **right**, indicating a **decrease in potency** (increase in $EC_{50}$). * **Efficacy:** Since the binding is reversible, the inhibitory effect of Flumazenil can be completely overcome by increasing the dose of Diazepam. Therefore, the maximal response ($E_{max}$) remains unchanged, meaning there is **no effect on efficacy**. 2. **Why Other Options are Incorrect:** * **Option B:** This describes **Non-competitive antagonism**. Non-competitive antagonists bind to allosteric sites or bind irreversibly, reducing the total number of available receptors and thus lowering the maximal response (efficacy). * **Option C:** This would imply no interaction at all. * **Option D:** This is characteristic of a **Non-competitive antagonist** where the $E_{max}$ is reduced but the $EC_{50}$ might remain unchanged. ### NEET-PG High-Yield Pearls * **Flumazenil** is the specific antidote for Benzodiazepine overdose but is **not** effective for Barbiturate or Alcohol toxicity. * **Competitive Antagonist:** Parallel shift of DRC to the right; $V_{max}$ (Efficacy) unchanged; $K_m$ (Potency) decreased. * **Non-competitive Antagonist:** Downward shift of DRC; $V_{max}$ (Efficacy) decreased; $K_m$ (Potency) usually unchanged. * **Inverse Agonist at BZD receptor:** Beta-carbolines (produce anxiety/seizures).

Q: Which one of the following drugs does not have an active metabolite?

Lisinopril. **Explanation The correct answer is **Lisinopril**. **1. Why Lisinopril is correct:** Most ACE inhibitors are **prodrugs** (e.g., Enalapril, Ramipril) that require hepatic conversion into their active "-at" forms (Enalaprilat, Ramiprilat) [2]. However, **Lisinopril** and **Captopril** are the two notable exceptions; they are already in their active form when administered and do not undergo metabolism to form active metabolites [1]. Lisinopril is excreted unchanged by the kidneys. **2. Analysis of Incorrect Options:** * **Diazepam:** This benzodiazepine has a very long half-life because it is metabolized into several active metabolites, including **Nordiazepam** (desmethyldiazepam) and **Oxazepam**. * **Propranolol:** This non-selective beta-blocker undergoes significant first-pass metabolism to form **4-hydroxypropranolol**, which possesses beta-blocking activity. * **Allopurinol:** Used in gout, Allopurinol is rapidly metabolized by xanthine oxidase to its active metabolite, **Alloxanthine (Oxypurinol)**. Alloxanthine has a much longer half-life and is responsible for the sustained inhibition of uric acid synthesis. **3. NEET-PG High-Yield Pearls:** * **ACE Inhibitor Mnemonic:** All ACE inhibitors are prodrugs except **C**aptopril and **L**isinopril (Remember: "**C**heck **L**iver" – these two don't need the liver for activation). * **Active Metabolites to Remember:** * Morphine $\rightarrow$ Morphine-6-glucuronide (more potent) * Spironolactone $\rightarrow$ Canrenone * Amitriptyline $\rightarrow$ Nortriptyline * Codeine $\rightarrow$ Morphine * Lisinopril is preferred in patients with liver disease because it does not require hepatic activation [1].

Q: A drug following first-order kinetics is administered by constant intravenous infusion at a rate of 10 mg/min. Its steady-state plasma concentration is 2 mg/L. If the dose rate is increased to 20 mg/min, what will be the new steady-state plasma concentration?

4 mg/L. ### Explanation **1. Why Option B is Correct:** The core concept here is **First-Order Kinetics**. In first-order kinetics, the rate of elimination is directly proportional to the plasma concentration [1]. For a drug administered by constant intravenous infusion, the steady-state concentration ($C_{ss}$) is determined by the formula: $\text{Dose Rate} = ext{Clearance (CL)} \times C_{ss}$ Rearranging this: $C_{ss} = \frac{\text{Dose Rate}}{\text{CL}}$ [2]. In first-order kinetics, **Clearance (CL) remains constant** regardless of the dose [1]. Therefore, $C_{ss}$ is directly proportional to the infusion rate. * Initial state: 10 mg/min results in 2 mg/L. * New state: The dose rate is doubled (20 mg/min). * Result: The $C_{ss}$ must also double. $2 \text{ mg/L} \times 2 = \mathbf{4 \text{ mg/L}}$. **2. Why Other Options are Incorrect:** * **Option A (6 mg/L):** This would imply a non-linear, disproportionate increase, which is not seen in first-order kinetics. * **Option C (3 mg/L):** This suggests a sub-proportional increase, which does not align with the linear relationship of first-order elimination. * **Option D (1 mg/L):** This would imply that increasing the dose decreases the concentration, which is physiologically impossible under these parameters. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Steady State:** It takes approximately **4 to 5 half-lives ($t_{1/2}$)** to reach steady state, regardless of the dose or infusion rate. * **Zero-Order Kinetics:** If a drug follows zero-order kinetics (e.g., Phenytoin, Ethanol, Aspirin at high doses), doubling the dose can lead to a massive, unpredictable increase in $C_{ss}$ because the elimination mechanisms are saturated [1]. * **Clearance:** In first-order kinetics, Clearance is constant; in zero-order kinetics, Clearance decreases as plasma concentration increases [1].

Q: Which drug has a wide therapeutic index?

Penicillin. ### Explanation **Therapeutic Index (TI)** is a quantitative measurement of a drug's safety. It is defined as the ratio of the dose that produces toxicity to the dose that produces a clinically desired effect ($TI = TD_{50} / ED_{50}$). **1. Why Penicillin is Correct:** Penicillin has a **wide therapeutic index**, meaning there is a large margin between the effective dose and the toxic dose. This is primarily because penicillin targets the bacterial cell wall (peptidoglycan synthesis), a structure that does not exist in human cells. Consequently, even very high doses are generally well-tolerated by the human body, unless the patient has a specific hypersensitivity/allergy. **2. Why the Other Options are Incorrect:** * **Digoxin (A):** A classic example of a **narrow therapeutic index** drug. It requires therapeutic drug monitoring (TDM) because the dose required to treat heart failure/arrhythmias is very close to the dose that causes life-threatening digitalis toxicity. * **Lithium (B):** Used in bipolar disorder, lithium has an extremely narrow window (therapeutic range: 0.6–1.2 mEq/L). Levels above 1.5 mEq/L can lead to severe neurotoxicity and renal impairment. * **Phenytoin (C):** This antiepileptic follows **zero-order kinetics** (saturation kinetics) at higher therapeutic concentrations. Small dose increases can lead to disproportionately large increases in plasma levels, causing toxicity (ataxia, nystagmus). **3. NEET-PG High-Yield Pearls:** * **Mnemonic for Narrow Therapeutic Index drugs:** "**W**arning, **T**hese **L**ethal **D**rugs **P**revent **C**uring" (**W**arfarin, **T**heophylline, **L**ithium, **D**igoxin, **P**henytoin/Phenobarbitone, **C**arbamazepine). * Drugs with a wide TI (e.g., Penicillin, Paracetamol, Benzodiazepines) are generally safer and do not require routine TDM. * **Low TI** = High risk of toxicity; **High TI** = Safer profile.

Q: Which of the following is not a prodrug?

Diazepam. **Explanation:** A **prodrug** is a pharmacologically inactive compound that must undergo metabolic conversion (usually in the liver) to become an active metabolite. **Diazepam** is the correct answer because it is an **active drug** itself. While it is metabolized into active metabolites like nordiazepam and oxazepam (contributing to its long duration of action), the parent compound possesses intrinsic therapeutic activity. **Analysis of Options:** * **Enalapril:** Most ACE inhibitors (except Captopril and Lisinopril) are prodrugs. Enalapril is converted by hepatic esterases into its active form, **Enalaprilat**. * **Sulindac:** This is a sulfoxide NSAID. It is inactive until metabolized into a **sulfide** derivative, which inhibits COX enzymes. This prodrug nature helps reduce direct gastric mucosal irritation. * **Cortisone:** This is a biologically inactive glucocorticoid. It must be converted into **Hydrocortisone (Cortisol)** by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) in the liver to be effective. **High-Yield NEET-PG Pearls:** 1. **Mnemonic for Prodrugs:** "**A**ll **P**harmacists **S**hould **C**an **D**eliver **E**very **M**edicine **I**n **L**iquid **S**tate" (**A**CEIs except Capto/Lisinopril, **P**roton Pump Inhibitors, **S**ulindac/Sulfasalazine, **C**yclophosphamide, **D**opa/Dipivefrine, **E**nalapril, **M**ercaptopurine, **I**rinotecan, **L**evodopa, **S**tatin/Spironolactone). 2. **Exceptions:** Captopril and Lisinopril are the only two ACE inhibitors that are **not** prodrugs. 3. **Clinical Significance:** Prodrugs may have poor efficacy in patients with severe liver disease due to impaired metabolic activation.

Q: What is the rate of drug elimination?

Clearance. **Explanation:** **1. Why Clearance is the Correct Answer:** **Clearance (CL)** is defined as the theoretical volume of plasma from which a drug is completely removed per unit of time (e.g., mL/min). It represents the **efficiency of drug elimination**. [1] Mathematically, it is expressed as: * **Rate of elimination = Clearance × Plasma Concentration (C)** [1] In first-order kinetics (followed by most drugs), clearance remains constant, meaning the rate of elimination is directly proportional to the plasma concentration. [2] **2. Analysis of Incorrect Options:** * **Half-life (T1/2):** This is the time required for the plasma concentration of a drug to reduce by 50%. While related to elimination, it is a measure of *time*, not the *rate* of volume cleared. * **Biotransformation:** This refers to the chemical alteration of a drug (metabolism), usually in the liver. While it is a *process* that contributes to elimination, it is not the definition of the rate itself. * **Bioavailability:** This is the fraction of an administered dose of unchanged drug that reaches the systematic circulation. It relates to *absorption*, not elimination. **3. High-Yield NEET-PG Clinical Pearls:** * **Zero-order Kinetics:** A few drugs (e.g., **P**henytoin, **A**lcohol, **W**arfarin, **S**alicylates—Mnemonic: **PAWS**) have a constant *rate* of elimination regardless of concentration because their metabolic enzymes are saturated. [2] * **Steady State:** It takes approximately **4 to 5 half-lives** to reach a steady-state concentration. * **Maintenance Dose Calculation:** Clearance is the most important pharmacokinetic parameter used to calculate the maintenance dose of a drug. * **Formula to remember:** $T_{1/2} = \frac{0.693 \times Vd}{CL}$. This shows that half-life is inversely proportional to clearance.

Question 1

The action of intravenous thiopentone is terminated by which mechanism?

Accepted Answer

Redistribution

Answer

Rapid renal excretion

Answer

Oxidation

Answer

Conjugation

Question 2

Which of the following is calculated as the ratio of the area under the curve (AUC) obtained by oral administration versus the AUC for intravenous administration of the same drug?

Accepted Answer

Bioavailability

Answer

Absorption

Answer

Clearance

Answer

Elimination rate constant

Question 3

A dose-response curve of diazepam was produced alone and in the presence of flumazenil. Which of the following is true regarding the effect of flumazenil on the graph?

Accepted Answer

Decrease in potency and no effect on efficacy

Answer

Decrease in potency and decrease in efficacy

Answer

No effect on potency and no effect on efficacy

Answer

No effect on potency and decrease in efficacy

Question 4

Which one of the following drugs does not have an active metabolite?

Accepted Answer

Lisinopril

Answer

Diazepam

Answer

Propranolol

Answer

Allopurinol

Question 5

A drug following first-order kinetics is administered by constant intravenous infusion at a rate of 10 mg/min. Its steady-state plasma concentration is 2 mg/L. If the dose rate is increased to 20 mg/min, what will be the new steady-state plasma concentration?

Accepted Answer

4 mg/L

Answer

6 mg/L

Answer

3 mg/L

Answer

1 mg/L

Question 6

Which of the following factors is affected by the bioavailability of a drug?

Accepted Answer

Dose of the drug

Answer

Half-life of the drug

Answer

Volume of distribution

Answer

pKa value

Question 7

Which drug has a wide therapeutic index?

Accepted Answer

Penicillin

Answer

Digoxin

Answer

Lithium

Answer

Phenytoin

Question 8

Which of the following is NOT a feature of drugs acting through receptors?

Accepted Answer

Dependence of action on lipophilicity

Answer

Structural specificity

Answer

High potency

Answer

Competitive antagonism

Question 9

Which of the following is not a prodrug?

Accepted Answer

Diazepam

Answer

Enalapril

Answer

Sulindac

Answer

Cortisone

Question 10

What is the rate of drug elimination?

Accepted Answer

Clearance

Answer

Half-life (T1/2)

Answer

Biotransformation

Answer

Bioavailability

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?